TrialHuman vaccines & immunotherapeutics2015

Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: A randomized, double-blinded, active control, phase III trial.

Yujia Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.